Recce Pharmaceuticals CEO and managing director James Graham talked with Proactive about the company’s pioneering work in synthetic anti-infectives, its personal family origins, and the global significance of its lead asset R327.
In the interview, Graham shared how a moment in his grandfather’s garage helped spark what would become Recce’s mission—developing a new class of antibiotics to fight drug-resistant infections. “I said, Pop, let’s start a company… and we’ll see where this discovery takes us,” Graham recalled.
R327 is now being trialled as a topical gel in what is the world’s largest diabetic foot infection trial, taking place in Indonesia. Graham explained that the trial came about after direct engagement from the Indonesian government, who recognised both the scale of local need and the strategic value of international cooperation.
Reflecting on Recce’s ten years on the ASX and nearly two decades since inception, Graham pointed to both clinical milestones and team growth as standout achievements. He highlighted Recce’s ability to work across all strains of bacteria, including drug-resistant infections, as well as its unique synthetic manufacturing approach, which may offer significant advantages over traditional antibiotics.
From a garage experiment to a listed biotech with global clinical trials, Recce’s story blends family legacy, entrepreneurial grit and bold innovation in the life sciences sector.
For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe to our channel, and turn on notifications so you don’t miss future updates.
#ReccePharmaceuticals #R327 #AntibioticResistance #SyntheticAntibiotics #BiotechInnovation #Superbugs #DiabeticFootInfections #ASXBiotech #InfectiousDiseases #ProactiveInvestors #LifeSciences #ClinicalTrials #HealthTech